ADAPTHEALTH CORP AHCO 深 沪
已收盘 08-01 16:00:00 美东时间
8.75
-0.220
-2.45%
华盛通- 最 高9.08
- 今 开8.90
- 成交量 123.87万股
- 最 低 8.575
- 昨 收 8.97
- 总市值 11.81亿
- 52周最高 11.70
- 市盈率 静 14.33
- 换手率 0.92%
- 52周最低 7.105
- 委 比 71.03%
- 总股本 1.35亿
- 历史最高 41.579
- 量 比 1.34
- 振 幅 5.63%
- 历史最低 6.37
- 每 手 1
- 风险率 0.89%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多High Quality, Increased Member Satisfaction, Better Access to Care and Improved Outcomes Highlight Alignment Healthcare’s Impact in 2024
Alignment Healthcare’s 2024 Impact Report highlights its commitment to improving care for seniors. Key achievements include a 35% increase in Care Anywhere program members, lower hospitalization rates, and higher member satisfaction with a Net Promoter Score of 61. Innovations in their AVA technology platform and a focus on data-driven care have also enhanced outcomes. The report underscores their dedication to compassionate, personalized senior ...
07-23 12:00
Athene Announces Fixed Income Investor Call
Athene, a subsidiary of Apollo Global Management, will host a Fixed Income Investor Call on August 12, 2025, at 10:00 AM ET. The call will feature updates on business trends, new business origination, investment portfolio, and capital. Materials and a live webcast will be available on Athene’s Investor Relations website at ir.athene.com. For more information, visit www.athene.com or contact Jeanne Hess at +1 646 768 7319.
07-16 11:45
Pelthos Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1 Million Private Placement
Pelthos Therapeutics Inc., formed through the merger of Channel Therapeutics and Ligand’s LNHC, will debut on the NYSE American exchange under ticker "PTHS" on July 2, 2025. The company plans to launch ZELSUVMI™, a novel topical gel for molluscum contagiosum, in July 2025. Concurrently, Pelthos secured $50.1 million in a private equity placement, including repayment of $18.8 million in prior bridge financing. The company aims to leverage its nitr...
07-02 11:00
AdaptHealth Completes Sale of Infusion Assets
AdaptHealth ( ($AHCO) ) has issued an announcement. On June 30, 2025, AdaptHeal...
07-01 04:53
Concentrix Posts Downbeat Earnings, Joins CorMedix And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining over ...
06-27 21:09
Pasithea Therapeutics Presents Updated Interim Data from Ongoing Phase 1 Study of PAS-004 at the ASCO Annual Meeting 2025
PAS-004, a next-generation macrocyclic MEK inhibitor developed by Pasithea Therapeutics, has shown preliminary clinical activity as a monotherapy in heavily pre-treated, refractory solid tumors. Interim Phase 1 study results presented at the 2025 ASCO Annual Meeting highlight stable disease in 10 out of 16 efficacy evaluable patients, with tumor reductions and prolonged survival. Notably, a patient with stage 4 BRAF-mutated melanoma achieved a 14...
06-02 12:02
美股大行评级 | 潜在涨幅754.7%！HC Wainwright & Co.：Alector获机构升目标价至10美元，维持"买入"评级
潜在涨幅754.7%！HC Wainwright & Co.：Alector获机构升目标价至10美元，维持"买入"评级
05-10 10:00
RBC Capital Maintains Outperform on AdaptHealth, Lowers Price Target to $13
RBC Capital analyst Ben Hendrix maintains AdaptHealth (NASDAQ:AHCO) with a Outperform and lowers the price target from $14 to $13.
05-09 00:54
AdaptHealth Analyst Ratings
Unity Software(U.US) reported fourth-quarter financial results after the market...
05-09 00:52
AdaptHealth (NASDAQ:AHCO) Takes On Some Risk With Its Use Of Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu,...
03-20 19:08
